SWOG clinical trial number
SWOG-7817

Treatment of Advanced Germ Cell Neoplasms of the Testis: Remission Induction with Vinblastine, Bleomycin with Low-Dose or High-Dose Cis-Platinum, Surgical Removal of all Residual Tumor Following Remission Induction; Maintenance Therapy with Cytoxan, Actinomycin-D, Adriamycin and Vinblastine

Closed
Phase
Abbreviated Title
Treatment of Advanced Germ Cell Neoplasms of the Testis: Remission Induction with Vinblastine, Bleomycin with Low-Dose or High-Dose Cis-Platinum, Surgical Removal of all Residual Tumor Following…
Activated
07/25/1978
Closed
04/14/1981

Publication Information Expand/Collapse

2017

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

JM Unger;M Leblanc;CD Blanke JAMA Oncology Oct 1;3(10):1345-1351

PMid: PMID28586789; PMC5710507

The impact of positive SWOG treatment trials on population survival

J Unger;M LeBlanc;C Blanke J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion

1984

Dose-response and dose-survival advantage for high versus low-dose Cisplatin combined with Vinblastine and Bleomycin in disseminated testicular cancer. A Southwest Oncology Group study.

MK Samson;SE Rivkin;SE Jones;JJ Costanzi;AF LoBuglio;RL Stephens;EA Gehan;GD Cummings Cancer 53:1029-1035

The Southwest Oncology Group study for advanced testicular cancer.

ED Crawford Seminars in Urology 2(4)

1981

Positive dose-response of high (H) versus low (L) dose cis- platinum (DDP), vinblastine (VLB) and bleomycin (Bleo) in disseminated germ cell neoplasms of the testis.

MK Samson;RL Stephens;RC Klugo ASCO #C-538